Prognostic significance of XRCC4 expression in hepatocellular carcinoma
PDF | HTML | How to cite
Metrics: PDF 1405 views | HTML 2182 views | ?
Jun Lu1,2,*, Xing-Zhizi Wang2,*, Tian-Qi Zhang2,*, Xiao-Ying Huang2, Jin-Guang Yao2, Chao Wang3, Zhong-Hong Wei4, Yun Ma5, Xue-Min Wu2, Chun-Ying Luo2, Qiang Xia1 and Xi-Dai Long1,2
1Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, P.R.China
2Department of Pathology, Youjiang Medical University for Nationalities, Baise 533000, P.R.China
3Department of Medicine, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, P.R.China
4Department of Tumor, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, P.R.China
5Department of Pathology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, P.R.China
*These authors have contributed equally to this work
Xi-Dai Long, email: [email protected]
Keywords: XRCC4, hepatocarcinoma, prognosis, TACE
Received: May 01, 2017 Accepted: August 29, 2017 Published: September 28, 2017
Background: Our previous investigations have shown that the variants of X-ray repair complementing 4 (XRCC4) may be involved in hepatocellular carcinoma (hepatocarcinoma) tumorigenesis. This study aimed to investigate the possible prognostic significance of XRCC4 expression for hepatocarcinoma patients and possible value for the selection of transarterial chemoembolization (TACE) treatment.
Materials and Methods: We conducted a hospital-based retrospective analysis (including 421 hepatocarcinoma cases) to analyze the effects of XRCC4 on hepatocarcinoma prognosis and TACE. The levels of XRCC4 expression were tested using immunohistochemistry. The sensitivity of cancer cells to anti-cancer drug doxorubicin was evaluated using the half-maximal inhibitory concentration (IC50).
Results: XRCC4 expression was significantly correlated with pathological features including tumor stage, liver cirrhosis, and micro-vessel density. XRCC4 expression was an independent prognostic factor of hepatocarcinoma, and TACE treatments had no effects on prognosis of hepatocarcinoma patients with high XRCC4 expression. More intriguingly, TACE improved the prognosis of hepatocarcinoma patients with low XRCC4 expression. Functionally, XRCC4 overexpression increased while XRCC4 knockdown reduced the IC50 of cancer cells to doxorubicin.
Conclusions: These results suggest that XRCC4 may be an independent prognostic factor for hepatocarcinoma patients, and that decreasing XRCC4 expression may be beneficial for post-operative adjuvant TACE treatment in hepatocarcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.